The Therapeutic Impact of New Migraine Discoveries
- 12 December 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 26 (34) , 6261-6281
Abstract
Background: Migraine is one of the most disabling neurological conditions and associated with high socio-economic costs. Though certain aspects of the pathomechanism of migraine are still incompletely understood, the leading hypothesis implicates the role of the activation of the trigeminovascular system. Triptans are considered to be the current gold standard therapy for migraine attacks; however, their use in clinical practice is limited. Prophylactic treatment includes non-specific approaches for migraine prevention. All these support the need for future studies in order to develop innovative anti-migraine drugs.Objective: The present study is a review of the current literature regarding new therapeutic lines in migraine research.Methods: A systematic literature search in the database of PUBMED was conducted concerning therapeutic strategies in a migraine published until July 2017.Results: Ongoing clinical trials with 5-HT1F receptor agonists and glutamate receptor antagonists offer promising new aspects for acute migraine treatment. Monoclonal antibodies against CGRP and the CGRP receptor are revolutionary in preventive treatment; however, further long-term studies are needed to test their tolerability. Preclinical studies show positive results with PACAP- and kynurenic acid-related treatments. Other promising therapeutic strategies (such as those targeting TRPV1, substance P, NOS, or orexin) have failed to show efficacy in clinical trials.Conclusion: Due to their side-effects, current therapeutic approaches are not suitable for all migraine patients. Especially frequent episodic and chronic migraine represents a therapeutic challenge for researchers. Clinical and preclinical studies are needed to untangle the pathophysiology of migraine in order to develop new and migraine-specific therapies.Keywords
Funding Information
- European Social Fund GINOP (GINOP-2.3.2-15-2016-00034)
- European Commissio (602633)
- Hungarian Brain Research Program (KTIA_13_NAPA-III/9)
This publication has 184 references indexed in Scilit:
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Neurogenic inflammation and the peripheral nervous system in host defense and immunopathologyNature Neuroscience, 2012
- The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trialsThe Journal of Headache and Pain, 2012
- A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological studyJournal of Neural Transmission, 2012
- Modifications on the carboxylic function of kynurenic acidJournal of Neural Transmission, 2011
- Kynurenines in Parkinson’s disease: therapeutic perspectivesJournal of Neural Transmission, 2011
- Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analogJournal of Pharmaceutical and Biomedical Analysis, 2011
- Kynurenic acid has a dual action on AMPA receptor responsesNeuroscience Letters, 2006
- Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headacheNeuroscience Letters, 1995
- Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cellsBiochemical and Biophysical Research Communications, 1989